University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Katherine Van Loon, M.D., M.P.H.

Gastrointestinal cancer specialist

Dr. Katherine Van Loon is a gastrointestinal cancer specialist, with a particular interest in colon cancer. Van Loon received a master's degree in public health (M.P.H.) from the Yale University School of Epidemiology and Public Health before attending the Medical College of Georgia. She completed a residency in internal medicine at Beth Israel Deaconess Medical Center, Harvard Medical School. She came to UCSF for her fellowship in oncology in 2009.

With her background in public health, Van Loon's research is focused on epidemiology and outcomes research in gastrointestinal malignancies. She has a longstanding interest in global health, and her research has also focused on the epidemiology of gastrointestinal cancers in the developing world.

Van Loon is a member of the American Society of Clinical Oncology. She received a Young Investigator Award from the ASCO Conquer Cancer Foundation in 2012.

Clinics

Gastrointestinal Surgery and Oncology Clinic
1600 Divisadero St., Fourth Floor
San Francisco, CA 94143-1705
Phone: (415) 353-9888
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. – 5 p.m.

Pancreas Center
1600 Divisadero St., Fourth Floor
San Francisco, CA 94143-1705
Phone (Pancreatic Cancer): (415) 353-9888
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. — 5 p.m.

Conditions & Treatments

More about Katherine Van Loon

Education

Medical College of Georgia 2006

Residencies

Beth Israel Deaconess Medical Center, Harvard Medical School, Internal Medicine 2009

Fellowships

UCSF Medical Center, Oncology 2011

Selected Research and Publications

  1. Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect. 2014 Nov 27.
  2. Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, O'Reilly EM, Fuchs C, Innocenti F, Venook AP. 25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). J Natl Cancer Inst. 2014 Aug; 106(8).
  3. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. Am J Clin Oncol. 2014 Jul 25.
  4. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?: A Pooled Analysis of Phase II Trials of Gemcitabine-Containing Doublets Plus Bevacizumab. Pancreas. 2014 Apr; 43(3):343-9.
  5. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer. 2014 Jun 15; 120(12):1780-6.
  6. Van Loon K, Venook AP. Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities. J Clin Oncol. 2014 Apr 1; 32(10):991-6.
  7. Van Loon K, Venook AP. Biomarkers in colon cancer: the chasm between expectations and reality. Oncology (Williston Park). 2013 Aug; 27(8):758, 763.
  8. Van Loon K, Atreya CE, Kelley RK, Venook AP. Gene Profiling in Colon Cancer: How to Integrate Profiling into Practice. Personalized Medicine in Oncology. 2013; 2(4):204-11.
  9. Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JA. Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. Clin Colorectal Cancer. 2013 Jun; 12(2):95-102.
  10. Van Loon K, Venook AP. Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain. J Natl Compr Canc Netw. 2012 Nov 1; 10(11):1379-86.
  11. Van Loon K, Venook AP. Metastatic colorectal cancer: a curable disease. Oncology (Williston Park). 2012 Mar; 26(3):275-6, 282.
  12. Van Loon K, Gill RM, McMahon P, Chigurupati R, Siddiqi I, Fox L, Damon L, McCalmont TH, Jordan R, Wolf J. 20q- clonality in a case of oral sweet syndrome and myelodysplasia. Am J Clin Pathol. 2012 Feb; 137(2):310-5.
  13. Van Loon K, Venook AP. Adjuvant treatment of colon cancer: what is next? Curr Opin Oncol. 2011 Jul; 23(4):403-9.
  14. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A. 2001 Nov 6; 98(23):13288-93.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.